Sally Hunsberger

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. doi request reprint Analysis of progression-free survival data using a discrete time survival model that incorporates measurements with and without diagnostic error
    Sally Hunsberger
    National Cancer Institute, Biostatistics Research Branch, Rockville, MD, USA
    Clin Trials 7:634-42. 2010
  2. pmc A comparison of phase II study strategies
    Sally Hunsberger
    Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 15:5950-5. 2009
  3. ncbi request reprint Dose escalation trial designs based on a molecularly targeted endpoint
    Sally Hunsberger
    Biometrics Research Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Stat Med 24:2171-81. 2005
  4. doi request reprint A finite mixture survival model to characterize risk groups of neuroblastoma
    Sally Hunsberger
    Biometric Research Branch, National Cancer Institute, 6130 Executive Boulevard, Rm 8120, Rockville, MD 20852, USA
    Stat Med 28:1301-14. 2009
  5. ncbi request reprint Testing logistic regression coefficients with clustered data and few positive outcomes
    Sally Hunsberger
    Biometric Research Branch, National Cancer Institute, Bethesda, MD 20892, U S A
    Stat Med 27:1305-24. 2008
  6. ncbi request reprint Design issues of randomized phase II trials and a proposal for phase II screening trials
    Lawrence V Rubinstein
    Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA
    J Clin Oncol 23:7199-206. 2005
  7. ncbi request reprint Proposal for the use of progression-free survival in unblinded randomized trials
    Boris Freidlin
    Biometric Research Branch and the Clinical Investigations Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 25:2122-6. 2007
  8. pmc Physical activity, weight control, and breast cancer risk and survival: clinical trial rationale and design considerations
    Rachel Ballard-Barbash
    Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, EPN 4005, Executive Blvd, Bethesda, MD 20892 7344, USA
    J Natl Cancer Inst 101:630-43. 2009
  9. pmc Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009
    Edward L Trimble
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7436, USA
    Int J Gynecol Cancer 20:1290-8. 2010
  10. ncbi request reprint Practical midcourse sample size modification in clinical trials
    Michael A Proschan
    National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    Control Clin Trials 24:4-15. 2003

Detail Information

Publications17

  1. doi request reprint Analysis of progression-free survival data using a discrete time survival model that incorporates measurements with and without diagnostic error
    Sally Hunsberger
    National Cancer Institute, Biostatistics Research Branch, Rockville, MD, USA
    Clin Trials 7:634-42. 2010
    ..The second method is considered to be the reference standard but is expensive, time consuming, and logistically difficult. The first method has measurement error associated with it, but, it is less expensive and easier to obtain...
  2. pmc A comparison of phase II study strategies
    Sally Hunsberger
    Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 15:5950-5. 2009
    ..In this article, we compare different phase II study strategies to determine the most efficient drug development path in terms of number of patients and length of time to conclusion of drug efficacy on overall survival...
  3. ncbi request reprint Dose escalation trial designs based on a molecularly targeted endpoint
    Sally Hunsberger
    Biometrics Research Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Stat Med 24:2171-81. 2005
    ..A limited simulation study is performed and the designs are compared with respect to the dose level at the end of escalation and the number of patients treated on study...
  4. doi request reprint A finite mixture survival model to characterize risk groups of neuroblastoma
    Sally Hunsberger
    Biometric Research Branch, National Cancer Institute, 6130 Executive Boulevard, Rm 8120, Rockville, MD 20852, USA
    Stat Med 28:1301-14. 2009
    ..The robustness of the model and the prediction method is examined via simulation by looking at misclassification rates under misspecified models...
  5. ncbi request reprint Testing logistic regression coefficients with clustered data and few positive outcomes
    Sally Hunsberger
    Biometric Research Branch, National Cancer Institute, Bethesda, MD 20892, U S A
    Stat Med 27:1305-24. 2008
    ..The proposed method is also useful when testing goodness-of-fit of logistic regression models using deciles-of-risk tables...
  6. ncbi request reprint Design issues of randomized phase II trials and a proposal for phase II screening trials
    Lawrence V Rubinstein
    Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA
    J Clin Oncol 23:7199-206. 2005
    ....
  7. ncbi request reprint Proposal for the use of progression-free survival in unblinded randomized trials
    Boris Freidlin
    Biometric Research Branch and the Clinical Investigations Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 25:2122-6. 2007
    ..This proposal, possibly combined with central review of progression scans for these two time points, essentially eliminates any bias, with little risk of major efficiency loss compared with using the reported progression times...
  8. pmc Physical activity, weight control, and breast cancer risk and survival: clinical trial rationale and design considerations
    Rachel Ballard-Barbash
    Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, EPN 4005, Executive Blvd, Bethesda, MD 20892 7344, USA
    J Natl Cancer Inst 101:630-43. 2009
    ....
  9. pmc Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009
    Edward L Trimble
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7436, USA
    Int J Gynecol Cancer 20:1290-8. 2010
    ..To review the current status of large phase academic clinical trials for women with ovarian cancer, address cross-cutting issues, and identify promising areas for future collaboration...
  10. ncbi request reprint Practical midcourse sample size modification in clinical trials
    Michael A Proschan
    National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    Control Clin Trials 24:4-15. 2003
    ..We show how to compute the p value and confidence interval for this two-stage procedure. If the original sample size is maintained, analysis of the data is the same as for a fixed sample procedure...
  11. ncbi request reprint On analyzing circadian rhythms data using nonlinear mixed models with harmonic terms
    Paul S Albert
    Biometric Research Branch, National Cancer Institute, Executive Plaza North, Bethesda, Maryland 20892 7434, USA
    Biometrics 61:1115-20; discussion 1120-2. 2005
    ..The proposed parametric approach provides an alternative to Wang et al.'s semiparametric approach and has the added advantage of being easy to implement in most statistical software packages...
  12. pmc Effective incorporation of biomarkers into phase II trials
    Lisa M McShane
    Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 15:1898-905. 2009
    ..A rational and coordinated approach to the inclusion of biomarker studies throughout the drug development process will be the key to attaining the goal of personalized medicine...
  13. ncbi request reprint Preliminary data release for randomized clinical trials of noninferiority: a new proposal
    Edward L Korn
    Biometric Research Branch and Clinical Investigations Branch, Division of Cancer Treatment and Diagnosis, EPN 8128, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 23:5831-6. 2005
    ..Examples are given demonstrating how the proposal would work, along with a discussion of possible objections to the proposal...
  14. ncbi request reprint Very high-dose methotrexate (33.6 g/m(2)) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P
    Paul C Nathan
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Leuk Lymphoma 47:2488-504. 2006
    ..VHD-MTX achieved similar survival to other CNS-directed therapies without the long-term impact on intelligence, but with substantial acute toxicities...
  15. ncbi request reprint Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system
    Clifford A Hudis
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:2127-32. 2007
    ....
  16. ncbi request reprint Innovative designs in behavioural trials
    Bruce Thompson
    Clinical Trials and Surveys Corporation, Suite 350, Village of Cross Keys, Baltimore, Maryland 21210, USA
    Stat Med 21:2981-9. 2002
    ..In this paper we use the design of the Raynaud's Treatment Study to demonstrate methods that can be used to control for non-specific effects and differential drop-out from the study...
  17. ncbi request reprint The effect of digoxin on the quality of life in patients with heart failure
    Ellis Lader
    New York University School of Medicine, New York, New York, USA
    J Card Fail 9:4-12. 2003
    ..A prespecified substudy evaluated the effect of digoxin therapy on health-related quality of life (HQOL) in a subset of these patients...